首页> 美国卫生研究院文献>Contemporary Oncology >Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy

【2h】

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy

机译：贝伐单抗联合FOLFOX化疗治疗的转移性结直肠癌患者超重与更好的预后相关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in metastatic CRC (mCRC). Whether BMI is a prognostic or predictive factor in mCRC is unclear. We aimed to assess efficacy outcomes according to BMI in patient with metastatic colorectal cancer treated with bevacizumab plus FOLFOX chemotherapy regimen in second-line treatment.

机译：先前的研究表明，高和低体重指数（BMI）与转移性CRC（mCRC）的不良预后相关。 BMI是mCRC的预后因素还是预测因素尚不清楚。我们旨在根据BMI评估在二线治疗中接受贝伐单抗联合FOLFOX化疗方案治疗的转移性结直肠癌患者的疗效。

著录项

期刊名称 Contemporary Oncology
作者
Bożena Cybulska-Stopa; Iwona Ługowska; Rafał Wiśniowski; Małgorzata Domagała-Haduch; Marcin Rajczykowski; Karolina Piejko; Ilona Bar-Letkiewicz; Rafał Suwiński; Krzysztof Regulski; Jacek Mackiewicz;
展开▼
作者单位

展开▼
年(卷),期 2020(24),1
年度 2020
页码 -1
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
metastatic colorectal cancer; obesity; bevacizumab; body mass index; time to progression;

机译：转移性结直肠癌;肥胖症;贝伐单抗;体重指数;进展时间;

相似文献

外文文献
中文文献
专利

1. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy [J] . Alonso-EspinacoV., CuatrecasasM., AlonsoV., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第11期

机译：RAC1b过表达与一线FOLFOX / XELOX化疗治疗的KRAS / BRAF WT转移性结直肠癌患者预后不良相关
2. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-Bevacizumab or FOLFIRI-bevacizumab: Results from ARIES, a bevacizumab observational cohort study [J] . BendellJ.C., Bekaii-SaabT.S., CohnA.L., The oncologist . 2012,第12期

机译：最初用FOLFOX-贝伐单抗或FOLFIRI-贝伐单抗治疗的转移性结直肠癌患者的治疗模式和临床结局：贝伐单抗观察性队列研究ARIES的结果
3. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) [J] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, BMC Medicine . 2013,第1期

机译：KRAS c.35 G的更差预后>接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Symptom trajectories in patients with lung cancer, colorectal cancer, and lymphoma during chemotherapy and posttreatment: A latent growth curve analysis [D] . Brant, Jeannine Marie 2008

机译：肺癌，大肠癌和淋巴瘤患者化疗和治疗后的症状轨迹：潜在生长曲线分析
6. Worse prognosis of KRAS c.35 G A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) [O] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, 2013

机译：KRAS c.35 G的较差预后接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者
7. Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) [O] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, 2013

机译：KRASc.35 G的不良预后>接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅